UK clinical trial regs are changing — here’s what’s happening
April 14, 2026 | HRA, MHRA, clinical trial
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
Change is coming to the UK’s clinical trials landscape – and it’s big. From 28 April 2026, updated Clinical Trial Regulations will come into play, representing the biggest shift in how we plan and deliver clinical trials in the UK in almost two decades.
The amendments, presented by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Health Research Authority (HRA), were co-created in partnership with patients, researchers, and industry representatives, and represent a new era in UK clinical research.
The amendments bring the regulations into alignment with current culture. By promoting transparency and clarifying expectations, they aim to enhance participant safety, increase trial diversity, reduce researcher burden, speed up approvals, and position the UK as a trusted global research leader.
Here, we highlight some of the key updates and what they could mean in practice.
1. Updates to language and definitions
One of the most noticeable updates is the modernisation of terminology:
- Definitions have been updated to align with current language and tone:
- ‘Subject’ is now ‘participant’
- ‘Trial site’ is now ‘trial location’
- ‘Amendment’ is now ‘modification’
- There are now three distinct categories of trial modification:
- Substantial modifications
- Modification of an important detail
- Minor modifications
- The definition of Chief Investigator (CI) has been updated to refer to a ‘healthcare professional’. This change means a wider range of registered clinical professions are eligible to act as CIs. Individuals are required to be appropriately qualified through education, training, and experience.
2. Integrated statutory review
Combined Review (MHRA and a Research Ethics Committee) is a system that allows researchers to apply for ethics and regulatory approval at the same time. It has worked in practice for years, but now it’s embedded in the regulations. This means:
- A single integrated submission rather than separate parallel processes
- Faster, clearer decisions and improved communication between stakeholders
- Defined timelines and expectations for regulators and sponsors
For trial teams, this simplifies planning, reduces rework, and supports better alignment between regulatory and ethics considerations.
Initial applications will be made using IRAS. Learn more about the process and whether you need to create an account here.
3. Transparency is now a legal requirement
For the first time, the UK has statutory transparency obligations for all clinical trials of investigational medicinal products (CTIMPs):
- Trials must be publicly registered in a recognised registry
- Results summaries must be published within 12 months
- Plain-language summaries should be offered to participants
This is no longer optional best practice, but law. Trial teams should create standard operating procedures (SOPs) for trial registration, result sharing, and the process of developing timely participant-ready communications.
4. Expectations for trial start and oversight
The updated regulations introduce clearer expectations around when trials should begin and how they should be overseen once approved.
- Trial approvals will no longer remain valid indefinitely. Sponsors are expected to recruit the first UK participant within two years of approval, unless extended
- There is a clearer emphasis on risk-proportionate oversight, meaning the level of monitoring and governance should reflect the level of risk posed by the trial
- Regulatory expectations are more explicitly aligned with international Good Clinical Practice (GCP) principles
For trial teams, this means planning for faster trial start-up and ensuring oversight arrangements are proportionate to the risks involved.
Things to start thinking about
With April just around the corner, you may want to:
- Update your SOPs, playbooks, and templates to reflect the new terminology and processes
- Train your teams on the regulatory changes and what’s expected operationally
- Make sure your quality checks and oversight processes cover the new transparency and trial start rules
- Plan trial registrations and results reporting processes ahead of time
These changes don’t rewrite the basics of ethical, well-run trials, but they do clearly define expectations and bring the UK closer to global standards.
Don’t forget — on the same day as these updated regulations, the latest GCP Guidelines will also take effect in the UK. All clinical trials should comply with the principles of GCP.
If you or your team would like a short briefing slide deck or a practical checklist based on these changes, drop us a line — we are happy to help.
This content was provided by Cuttsy + Cuttsy
Company Details
Latest Content from Cuttsy + Cuttsy
From cloudy to clear: visualising complex data privacy information
Discover how clear communication principles can transform complex clinical research topics, as we conclude our Health Literacy series with a practical example on participant data transparency.
UK clinical trial regs are changing — here’s what’s happening
Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.
The invisible influence on trial retention: why caregivers must be part of the plan
Caregivers are vital to clinical trial retention, yet often overlooked—this article highlights their challenges, impact, and how to better support them.
Where it all began: why we wrote ‘The Site Factor’
Discover the story behind ‘The Site Factor’ and how understanding site teams’ experiences can transform clinical trials for participants and researchers alike.
From text to context: Helping patients see side effects clearly
Discover how thoughtful design, clear language, and structured visuals can transform overwhelming side effect information into accessible, actionable insights for patients in our latest Health Literacy series.
Why patient engagement must come first in rare disease trials
Explore why patient engagement is the cornerstone of successful rare disease trials, emphasising the importance of designing studies around the realities of patients' lives to build trust and improve outcomes.
New Cuttsy+Cuttsy research shows why site support matters more than ever
Cuttsy+Cuttsy's upcoming report, 'The site factor: Where protocol meets practice in clinical trials', delves into the critical role of site staff in clinical research, offering insights into their daily challenges,...
Cuttsy+Cuttsy becomes employee owned
Cuttsy+Cuttsy announces its transition to employee ownership, celebrating 15 years of prioritising clients, patients, and its team while continuing under the leadership of founders Caroline Benson and Mathew Cutts.
Clinical research in 2026: The trends shaping tomorrow
Discover the key trends shaping clinical research in 2026, from patient-centric approaches to empowering site staff and fostering stronger human connections.
From overwhelming to actionable: Bringing lifestyle guidance to life
Discover how clear communication and health literacy principles can transform complex patient materials into simple, engaging, and empowering health information.